Cargando…

Hybrid (18)F-florbetapir PET/MRI for assessing myelin recovery in GFAP-A patients

Glial fibrillary acidic protein astrocytopathy (GFAP-A) is a rare autoimmune disease of the central nervous system that was newly reported in 2016. Previous studies have speculated that the pathological mechanism and clinical outcome of GFAP-A lie in the demyelination of the central nervous system,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meng, Huanyu, Zheng, Shuyu, Yuan, Shaicun, Zhou, Qinming, Gao, Yining, Ni, You, He, Lu, Yin, Dou, Zhang, Min, Chen, Sheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	De Gruyter 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9186510/ https://www.ncbi.nlm.nih.gov/pubmed/35795195 http://dx.doi.org/10.1515/tnsci-2022-0223

Ejemplares similares

(18)F-florbetapir PET/MRI for quantitatively monitoring myelin loss and recovery in patients with multiple sclerosis: A longitudinal study
por: Zhang, Min, et al.
Publicado: (2021)

Operationalizing the centiloid scale for [(18)F]florbetapir PET studies on PET/MRI
por: Coath, William, et al.
Publicado: (2023)

(18)F-florbetapir PET as a marker of myelin integrity across the Alzheimer’s disease spectrum
por: Moscoso, Alexis, et al.
Publicado: (2021)

(18)F-florbetapir PET/MRI for quantitatively monitoring demyelination and remyelination in acute disseminated encephalomyelitis
por: Zhang, Min, et al.
Publicado: (2019)

Radiation dosimetry of florbetapir F 18
por: Joshi, Abhinay D, et al.
Publicado: (2014)

[(18)F]Florbetapir PET/MR imaging to assess demyelination in multiple sclerosis
por: Carotenuto, Antonio, et al.
Publicado: (2019)

Dual-phase [18F]florbetapir in frontotemporal dementia
por: Asghar, Michael, et al.
Publicado: (2018)

Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter study
por: Doraiswamy, P M, et al.
Publicado: (2014)

PET imaging of 18F-florbetapir in cognitively impaired individuals: Lack of activity within the cerebellar cortex
por: Meyer, Michael A., et al.
Publicado: (2018)

Using PET with (18)F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment
por: Camus, V., et al.
Publicado: (2012)

A Routine PET/CT Protocol with Streamlined Calculations for Assessing Cardiac Amyloidosis Using (18)F-Florbetapir
por: Osborne, Dustin R., et al.
Publicado: (2015)

Pilot Study of F18-Florbetapir in the Early Evaluation of Cardiac Amyloidosis
por: Sperry, Brett W., et al.
Publicado: (2021)

PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with (18)F-AV-133 (florbenazine) in patients with Alzheimer’s disease and Lewy body disorders
por: Siderowf, Andrew, et al.
Publicado: (2014)

FoxP3(−) Tr1 Cell in Generalized Myasthenia Gravis and Its Relationship With the Anti-AChR Antibody and Immunomodulatory Cytokines
por: Meng, Huanyu, et al.
Publicado: (2021)

Tracer‐specific reference tissues selection improves detection of (18)F‐FDG, (18)F‐florbetapir, and (18)F‐flortaucipir PET SUVR changes in Alzheimer's disease
por: Li, Yanxiao, et al.
Publicado: (2022)

Antibody-mediated autoimmune encephalitis evaluated by (18)F-DPA714 PET/MRI
por: Shen, Ruinan, et al.
Publicado: (2022)

Non-invasive Standardised Uptake Value for Verification of the Use of Previously Validated Reference Region for [(18)F]Flortaucipir and [(18)F]Florbetapir Brain PET Studies
por: de Vries, Bart M., et al.
Publicado: (2021)

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2014)

Cortical florbetapir-PET amyloid load in prodromal Alzheimer’s disease patients
por: Saint-Aubert, Laure, et al.
Publicado: (2013)

Lacrimal gland uptake on F-18 florbetapir amyloid positron emission tomography scan
por: Itani, Malak, et al.
Publicado: (2017)

Quantification of [(18)F]florbetapir: A test–retest tracer kinetic modelling study
por: Golla, Sandeep SV, et al.
Publicado: (2018)

Clinical impact of amyloid PET using (18)F-florbetapir in patients with cognitive impairment and suspected Alzheimer’s disease: a multicenter study
por: Matsuda, Hiroshi, et al.
Publicado: (2022)

Head-to-head comparison of relative cerebral blood flow derived from dynamic [(18)F]florbetapir and [(18)F]flortaucipir PET in subjects with subjective cognitive decline
por: Tuncel, Hayel, et al.
Publicado: (2023)

Extracardiac (18)F-florbetapir imaging in patients with systemic amyloidosis: more than hearts and minds
por: Wagner, T., et al.
Publicado: (2018)

Classification of negative and positive (18)F-florbetapir brain PET studies in subjective cognitive decline patients using a convolutional neural network
por: de Vries, Bart Marius, et al.
Publicado: (2020)

Multi-contrast attenuation map synthesis for PET/MR scanners: assessment on FDG and Florbetapir PET tracers
por: Burgos, Ninon, et al.
Publicado: (2015)

Comparison between PET template-based method and MRI-based method for cortical quantification of florbetapir (AV-45) uptake in vivo
por: Saint-Aubert, L., et al.
Publicado: (2013)

A consecutive case series experience with [(18) F] florbetapir PET imaging in an urban dementia center: impact on quality of life, decision making, and disposition
por: Mitsis, Effie M, et al.
Publicado: (2014)

Plasma Aβ analysis using magnetically-labeled immunoassays and PET (18)F-florbetapir binding in non-demented patients with major depressive disorder
por: Wu, Kuan-Yi, et al.
Publicado: (2018)

The use of back propagation neural networks and (18)F-Florbetapir PET for early detection of Alzheimer’s disease using Alzheimer’s Disease Neuroimaging Initiative database
por: Ozsahin, Ilker, et al.
Publicado: (2019)

Development of software for measuring brain amyloid accumulation using (18)F‐florbetapir PET and calculating global Centiloid scale and regional Z‐score values
por: Matsuda, Hiroshi, et al.
Publicado: (2023)

Florbetapir Regional Distribution in Cerebral Amyloid Angiopathy and Alzheimer’s Disease: A PET Study
por: Planton, Mélanie, et al.
Publicado: (2020)

Reference tissue normalization in longitudinal (18)F-florbetapir positron emission tomography of late mild cognitive impairment
por: Shokouhi, Sepideh, et al.
Publicado: (2016)

Author Correction: Plasma Aβ analysis using magnetically-labeled immunoassays and PET (18)F-florbetapir binding in non-demented patients with major depressive disorder
por: Wu, Kuan-Yi, et al.
Publicado: (2019)

Application of Haralick texture features in brain [(18)F]-florbetapir positron emission tomography without reference region normalization
por: Campbell, Desmond L, et al.
Publicado: (2017)

[18F]Florbetapir positron emission tomography: identification of muscle amyloid in inclusion body myositis and differentiation from polymyositis
por: Lilleker, James B, et al.
Publicado: (2019)

Repeatability of parametric methods for [(18)F]florbetapir imaging in Alzheimer’s disease and healthy controls: A test–retest study
por: Verfaillie, Sander CJ, et al.
Publicado: (2020)

Partial Volume Correction Increases the Sensitivity of 18F-Florbetapir-Positron Emission Tomography for the Detection of Early Stage Amyloidosis
por: Teipel, Stefan J., et al.
Publicado: (2021)

APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study
por: Ramanan, Vijay K., et al.
Publicado: (2013)

Spill-in counts in the quantification of (18)F-florbetapir on Aβ-negative subjects: the effect of including white matter in the reference region
por: López-González, Francisco Javier, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_smscakqu3b5g876orcfj8feplv